Home LiteratureArticle Details
PMID: 15469908 Published · epublish English Journal Article

Position- and orientation-specific enhancement of topoisomerase I cleavage complexes by triplex DNA structures.

Nucleic acids research ·Vol. 32 ·No. 17 ·2004-00-00 ·Pages 5163-73

Antony S, Arimondo PB, Sun JS, Pommier Y

Abstract

Topoisomerase I (Top1) activities are sensitive to various endogenous base modifications, and anticancer drugs including the natural alkaloid camptothecin. Here, we show that triple helix-forming oligonucleotides (TFOs) can enhance Top1-mediated DNA cleavage by affecting either or both the nicking and the closing activities of Top1 depending on the position and the orientation of the triplex DNA structure relative to the Top1 site. TFO binding 1 bp downstream from the Top1 site enhances cleavage by inhibiting religation and to a lesser extent DNA nicking. In contrast, TFO binding 4 bp downstream from the Top1 site enhances DNA nicking especially when the 3' end of the TFO is proximal to the Top1 site. However, when the orientation of the triplex is inverted, with its 5' terminus 4 bp downstream from the Top1 site, religation is also inhibited. These position- and orientation-dependent effects of triplex structures on the Top1-mediated DNA cleavage and religation are discussed in the context of molecular modeling and effects of TFO on DNA twist and mobility at the duplex/triplex junction.

MeSH Terms
Base Sequence DNA/chemistry,metabolism DNA Topoisomerases, Type I/metabolism Enzyme Activation Models, Molecular Nucleic Acid Conformation
Chemicals
triplex DNA DNA DNA Topoisomerases, Type I
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Antony Smitha
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255, USA.
Arimondo Paola B
Sun Jian-Sheng
Pommier Yves
References (52)
52 references, click to expand
  1. Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine.
    J Biol Chem. 1999 Mar 26;274(13):8516-23 PMID: 10085084
  2. Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures.
    J Mol Biol. 1999 Sep 24;292(3):685-96 PMID: 10497031
  3. Stabilities of intrastrand pyrimidine motif DNA and RNA triple helices.
    Nucleic Acids Res. 2000 Feb 1;28(3):770-5 PMID: 10637329
  4. Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages.
    Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2040-5 PMID: 10688881
  5. Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA.
    Biochemistry. 2000 Jun 13;39(23):6832-40 PMID: 10841763
  6. Position-specific trapping of topoisomerase I-DNA cleavage complexes by intercalated benzo[a]- pyrene diol epoxide adducts at the 6-amino group of adenine.
    Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10739-44 PMID: 10995470
  7. Recombinogenic flap ligation pathway for intrinsic repair of topoisomerase IB-induced double-strand breaks.
    Mol Cell Biol. 2000 Nov;20(21):8059-68 PMID: 11027276
  8. Topoisomerase I-mediated DNA damage.
    Adv Cancer Res. 2001;80:189-216 PMID: 11034544
  9. Interaction of human DNA topoisomerase I with G-quartet structures.
    Nucleic Acids Res. 2000 Dec 15;28(24):4832-8 PMID: 11121473
  10. Triplex-forming molecules for modulation of DNA information processing.
    Curr Opin Mol Ther. 2000 Jun;2(3):288-96 PMID: 11249623
  11. Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase I-mediated DNA cleavage to a specific site.
    Bioconjug Chem. 2001 Jul-Aug;12(4):501-9 PMID: 11459453
  12. DNA topoisomerases: structure, function, and mechanism.
    Annu Rev Biochem. 2001;70:369-413 PMID: 11395412
  13. Design and optimization of camptothecin conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage by topoisomerase I.
    J Biol Chem. 2002 Feb 1;277(5):3132-40 PMID: 11724801
  14. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
    Biochemistry. 2002 Feb 5;41(5):1428-35 PMID: 11814334
  15. Interaction of human nuclear topoisomerase I with guanosine quartet-forming and guanosine-rich single-stranded DNA and RNA oligonucleotides.
    J Biol Chem. 2002 Mar 15;277(11):8906-11 PMID: 11756434
  16. Cellular roles of DNA topoisomerases: a molecular perspective.
    Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 PMID: 12042765
  17. 8-Oxoguanine rearranges the active site of human topoisomerase I.
    Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12102-7 PMID: 12209008
  18. Unusual DNA conformations: implications for telomeres.
    Curr Med Chem Anticancer Agents. 2002 Sep;2(5):627-44 PMID: 12678729
  19. Spatial organization of topoisomerase I-mediated DNA cleavage induced by camptothecin-oligonucleotide conjugates.
    Nucleic Acids Res. 2003 Jul 15;31(14):4031-40 PMID: 12853620
  20. Guarding the genome: electrostatic repulsion of water by DNA suppresses a potent nuclease activity of topoisomerase IB.
    Mol Cell. 2003 Jul;12(1):199-208 PMID: 12887905
  21. Site-specific DNA transesterification by vaccinia topoisomerase: effects of benzo[alpha]pyrene-dA, 8-oxoguanine, 8-oxoadenine and 2-aminopurine modifications.
    J Biol Chem. 2003 Oct 24;278(43):42170-7 PMID: 12909623
  22. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
    Cancer Res. 2003 Nov 1;63(21):7428-35 PMID: 14612542
  23. Repair of and checkpoint response to topoisomerase I-mediated DNA damage.
    Mutat Res. 2003 Nov 27;532(1-2):173-203 PMID: 14643436
  24. Triplex-forming oligonucleotide target sequences in the human genome.
    Nucleic Acids Res. 2004;32(1):354-60 PMID: 14726484
  25. Resolution of undistorted symmetric immobile DNA junctions by vaccinia topoisomerase I.
    Biochemistry. 2004 Feb 17;43(6):1520-31 PMID: 14769028
  26. Oligonucleotide interactions. 3. Circular dichroism studies of the conformation of deoxyoligonucleotides.
    Biopolymers. 1970;9(9):1059-77 PMID: 5449435
  27. A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin.
    Cell. 1985 Jun;41(2):541-51 PMID: 2985282
  28. Topoisomerase I has a strong binding preference for a conserved hexadecameric sequence in the promoter region of the rRNA gene from Tetrahymena pyriformis.
    Nucleic Acids Res. 1985 Mar 11;13(5):1543-57 PMID: 2987828
  29. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
    J Biol Chem. 1985 Nov 25;260(27):14873-8 PMID: 2997227
  30. Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin.
    Nucleic Acids Res. 1988 Dec 9;16(23):11157-70 PMID: 2849758
  31. Topology and formation of triple-stranded H-DNA.
    Science. 1989 Mar 24;243(4898):1571-6 PMID: 2648571
  32. The flexibility of the nucleic acids: (II). The calculation of internal energy and applications to mononucleotide repeat DNA.
    J Biomol Struct Dyn. 1986 Apr;3(5):989-1014 PMID: 3271422
  33. The definition of generalized helicoidal parameters and of axis curvature for irregular nucleic acids.
    J Biomol Struct Dyn. 1988 Aug;6(1):63-91 PMID: 2482765
  34. Eukaryotic topoisomerase I-DNA interaction is stabilized by helix curvature.
    Nucleic Acids Res. 1991 Mar 25;19(6):1235-41 PMID: 1851553
  35. Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I.
    J Mol Biol. 1992 Dec 20;228(4):1025-30 PMID: 1335513
  36. A computational and experimental study of the bending induced at a double-triple helix junction.
    Biophys Chem. 1992 Dec;45(2):143-52 PMID: 1286149
  37. A possible family of B-like triple helix structures: comparison with the Arnott A-like triple helix.
    Biochemistry. 1993 Mar 2;32(8):2098-103 PMID: 8448168
  38. Control of gene expression by triple helix-forming oligonucleotides. The antigene strategy.
    Ann N Y Acad Sci. 1992 Oct 28;660:27-36 PMID: 1340131
  39. DNA comes in many forms.
    Gene. 1993 Dec 15;135(1-2):99-109 PMID: 8276285
  40. DNA topoisomerases: essential enzymes and lethal targets.
    Annu Rev Pharmacol Toxicol. 1994;34:191-218 PMID: 8042851
  41. Effect of a triplex-binding ligand on parallel and antiparallel DNA triple helices using short unmodified and acridine-linked oligonucleotides.
    Biochemistry. 1994 Dec 27;33(51):15338-47 PMID: 7803397
  42. Thermodynamics of an intramolecular DNA triple helix: a calorimetric and spectroscopic study of the pH and salt dependence of thermally induced structural transitions.
    J Mol Biol. 1995 May 5;248(3):679-95 PMID: 7752233
  43. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
    Biochemistry. 1995 May 30;34(21):7200-6 PMID: 7766631
  44. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.
    Semin Oncol. 1996 Feb;23(1 Suppl 3):3-10 PMID: 8633251
  45. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
    Mol Pharmacol. 1996 Nov;50(5):1095-102 PMID: 8913340
  46. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I.
    J Biol Chem. 1997 Mar 21;272(12):7792-6 PMID: 9065442
  47. Kinetic analysis of DNA and RNA strand transfer reactions catalyzed by vaccinia topoisomerase.
    J Biol Chem. 1997 Jun 20;272(25):15721-8 PMID: 9188465
  48. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects.
    J Biol Chem. 1997 Oct 17;272(42):26441-7 PMID: 9334220
  49. DNA topoisomerase I-mediated formation of structurally modified DNA duplexes. Effects of metal ions and topoisomerase I inhibitors.
    Biochemistry. 1998 Feb 24;37(8):2691-700 PMID: 9485420
  50. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA.
    Science. 1998 Mar 6;279(5356):1504-13 PMID: 9488644
  51. A model for the mechanism of human topoisomerase I.
    Science. 1998 Mar 6;279(5356):1534-41 PMID: 9488652
  52. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme.
    Biochim Biophys Acta. 1998 Oct 1;1400(1-3):83-105 PMID: 9748515
Article Info
Journal
Nucleic acids research
Abbr.
Nucleic Acids Res
ISSN
1362-4962
DOI
10.1093/nar/gkh847
Published
2004-00-00
Epub
2004-00-04
Pages
5163-73
Language
English
Region
England
NLM ID
0411011
PMCID
PMC521660
Subset
IM
External Links
PubMed source DOI: 10.1093/nar/gkh847 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2